NCT00788905|Unknown
Comparison of Conventional Dialysis and the Allient System
Uremic Toxin Removal, Blood Cell Kinetics, and Inflammatory Response in Patients Treated With the Allient System
Loading search results
Uremic Toxin Removal, Blood Cell Kinetics, and Inflammatory Response in Patients Treated With the Allient System
Sponsor study identifier
interventional
40
1 country
3
Study Start
November 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2011
Actual (reported)Study Completion
January 2014
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of the study to determine whether the level of inflammation may be decreased, the lifespan of red blood cells increased and the clearance of waste products in the blood improved through the use of the Allient System as compared to conventional hemodialysis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2014
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 23, 2008
Actual (reported)November 2008
Date type not reportedThis date has not been verified as actual or estimated.
November 11, 2008
Actual (reported)February 2011
Actual (reported)January 2014
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Clearance of specific waste products from blood determined through subject blood and dialysate samples
3 weeks
Inflammation as determined by levels of specific inflammatory markers
3 weeks
Red blood cell lifespan determined through a measurement of CO in the subject's breath
3 weeks
Subject will continue conventional hemodialysis therapy for one week ("no intervention" phase) and then swtich to the Allient system for two weeks ("active comparator" phase).
The Allient System uses a different type of blood pump and a lower volume of dialysate.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Irving Place Dialysis Center
New York, New York, 10003, United States
Upper Manhattan Dialysis Center
New York, New York, 10025, United States
Yorkville Dialysis Center
New York, New York, 10128, United States
Rosales L, Thijssen S, Kruse A, Sipahioglu MH, Hirachan P, Raimann JG, Kuntsevich V, Carter M, Levin NW, Kotanko P. Inflammatory Response to Sorbent Hemodialysis. ASAIO J. 2015 Jul-Aug;61(4):463-7. doi: 10.1097/MAT.0000000000000212.
Nathan W. Levin, MD
Renal Research Institute
Peter Kotanko, MD
Renal Research Institute
First Submitted
September 23, 2008
First Posted
November 11, 2008
Study Start
November 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2011
Actual (reported)Vitamin D and Arteriovenous Fistulae
Contact the study team to confirm eligibility.
Study Completion
January 2014
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 29, 2013
Record last verified: 2013-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: